Fibrolamellar Carcinoma Overview

Save information for later
Sign Up

Learn About Fibrolamellar Carcinoma

What is the definition of Fibrolamellar Carcinoma?
Many people with early FLC have no signs or symptoms of the condition. When present, symptoms are often nonspecific (i.e. abdominal pain, weight loss, malaise) and blamed on other, more common conditions. The exact underlying cause of FLC is poorly understood. Unlike other forms of liver cancer, FLC typically occurs in the absence of underlying liver inflammation or scarring; thus, specific risk factors for this condition remain unidentified.
What are the alternative names for Fibrolamellar Carcinoma?
  • Fibrolamellar carcinoma
  • Eosinophilic glassy cell hepatoma
  • Eosinophilic hepatocellular carcinoma with lamellar fibrosis
  • FHCC
  • FL-HCC
  • Fibrolamellar hepatocarcinoma
  • Fibrolamellar hepatocellular carcinoma
  • Fibrolamellar oncocytic hepatoma
  • Hepatocellular carcinoma with increased stromal fibrosis
  • Polygonal cell hepatocellular carcinoma with fibrous stroma
Who are the top Fibrolamellar Carcinoma Local Doctors?
Elite in Fibrolamellar Carcinoma
Dr. Ghassan K. Abou-Alfa
Oncology
Elite in Fibrolamellar Carcinoma
Dr. Ghassan K. Abou-Alfa
Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ghassan Abou-Alfa is an Oncologist in New York, New York. Dr. Abou-Alfa is rated as an Elite provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Liver Cancer, Cholangiocarcinoma (Bile Duct Cancer), Fibrolamellar Carcinoma, Liver Embolization, and Pancreaticoduodenectomy.

Elite in Fibrolamellar Carcinoma
Dr. Mark Yarchoan
Oncology
Elite in Fibrolamellar Carcinoma
Dr. Mark Yarchoan
Oncology

Johns Hopkins University

600 N Wolfe St, Blalock 266, 
Baltimore, MD 
410-502-4340
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Yarchoan is an Oncologist in Baltimore, Maryland. Dr. Yarchoan is rated as an Elite provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Pancreatic Cancer, and Hepatectomy. Dr. Yarchoan is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Fibrolamellar Carcinoma
Dr. Ahmed O. Kaseb
Oncology
Elite in Fibrolamellar Carcinoma
Dr. Ahmed O. Kaseb
Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ahmed Kaseb is an Oncologist in Houston, Texas. Dr. Kaseb is rated as an Elite provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Liver Cancer, Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Hepatectomy, and Liver Embolization.

View All Doctors
What are the latest Fibrolamellar Carcinoma Clinical Trials?
DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma
DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma
Enrollment Status: Recruiting
Publish Date: September 18, 2025
Intervention Type: Biological, Drug, Procedure
Study Phase: Phase 1/Phase 2

Summary: This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). DT2216 is an anti-apoptotic protein B-cell lymphoma-ex...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Pilot Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
A Pilot Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
Who is this study for: Patients with Fibrolamellar Hepatocellular Carcinoma
Enrollment Status: Recruiting
Publish Date: July 09, 2025
Intervention Type: Drug
Study Drugs: DNAJB1-PRKACA Peptide Vaccine, Nivolumab, Ipilimumab
Study Phase: Phase 1

Summary: The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC and with non-FLC solid tumors and to assess the T-cell response.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center